Merck Prices Hepatitis C Drug Lower Than Rivals in Crowded Field
- FDA approves drug that will compete against Gilead, AbbVie
- Agency says Merck drug is approved for genotypes 1 and 4
This article is for subscribers only.
Merck & Co. has priced its new hepatitis C drug, just approved by U.S. regulators, at a sharp discount to competing therapies from Gilead Sciences Inc. and AbbVie Inc., a move that could start a new price war in the field.
The U.S. Food and Drug Administration said Thursday that it approved Merck’s single pill, which combines the medications grazoprevir and elbasvir, after granting the drug a priority review in July.